MDRPEDIA RECORDELITE · TIER IILIVING
Moncef Slaoui
Immunology (Vaccine Development) · Operation Warp Speed (US Government) · Philadelphia, Morocco
- h-index (OpenAlex)
- 50
- Papers on record
- 10
- Citations to these papers
- 3,143
- Stature
- Tier II
EVIDENCE RECORD
What this record is built on
Compared with the register: Internal Medicine · Morocco · How it works
I · SCHOLARSHIP
- h-index
- 50 · 70th pct
- Papers on record
- 10
- Citations received
- 3,143
II · PRACTICE
- Licence
- Not yet checked
- Board certification
- —
- Registration ID
- —
- Institutions
- 2
III · LEARNING & TEACHING
- Trainees traced
- Not yet traced
- Mentors traced
- Not yet traced
- Invited talks
- —
IV · PEER STANDING
- Honours
- 1
- Techniques pioneered
- —
- Ethics mark
- Not yet audited
Not on this record by design:Star ratingsAnonymous reviewsPaid placement
Record
Moncef Slaoui is a Moroccan-Belgian-American immunologist who served as chief scientific advisor for Operation Warp Speed, the US government program that developed COVID-19 vaccines in record time. Previously he led vaccine development at GlaxoSmithKline for 30 years, overseeing 14 new vaccines including those for cervical cancer and malaria.
IN PLAIN WORDS
- Research is cited 3K+ times by other doctors and scientists
- Currently at Operation Warp Speed (US Government) in Philadelphia, Morocco
What they treat and study
SPECIALTIES
CLINICAL KNOWLEDGE AND PROCEDURES
Institutions
- Operation Warp Speed (US Government)
- GlaxoSmithKline
QUESTIONS YOU MIGHT ASK AT A FIRST VISIT
- Is a procedure needed now, or can medicines and lifestyle changes help first?
- What are the risks and benefits of each option for someone like me?
- How many similar cases does your team see, and who will be involved in my care?
- Who do I contact if symptoms come back after treatment?
Landmark papers
- Papers on record
- 10
- Citations received
- 3,143
PUBLISHED IN New England Journal of Medicine · The Journal of Infectious Diseases · Proceedings of the National Academy of Sciences · Vaccine · Infection and Immunity
- 1997A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine against<i>Plasmodium falciparum</i><i>Malaria</i>New England Journal of Medicinedoi 10.1056/nejm199701093360202879 citations
- 2002Glycoprotein-D–Adjuvant Vaccine to Prevent Genital HerpesNew England Journal of Medicinedoi 10.1056/nejmoa011915789 citations
- 1995Safety, Immunogenicity, and Efficacy of a Recombinantly Produced Plasmodium falciparum Circumsporozoite Protein-Hepatitis B Surface Antigen Subunit VaccineThe Journal of Infectious Diseasesdoi 10.1093/infdis/171.6.1576329 citations
- 1998Long‐Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria VaccineThe Journal of Infectious Diseasesdoi 10.1086/515657236 citations
- 2020Developing Safe and Effective Covid Vaccines — Operation Warp Speed’s Strategy and ApproachNew England Journal of Medicinedoi 10.1056/nejmp2027405225 citations
Show all 10 papersShow fewer papers
- 1986Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen.Proceedings of the National Academy of Sciencesdoi 10.1073/pnas.83.17.6578161 citations
- 1998Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant systemVaccinedoi 10.1016/s0264-410x(97)00254-5157 citations
- 1999Potent Induction of Focused Th1‐Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a Recombinant<i>Plasmodium falciparum</i>Malaria VaccineThe Journal of Infectious Diseasesdoi 10.1086/315074156 citations
- 2003Herpes Simplex Virus (HSV) Type 2 Glycoprotein D Subunit Vaccines and Protection against Genital HSV‐1 or HSV‐2 Disease in Guinea PigsThe Journal of Infectious Diseasesdoi 10.1086/374002115 citations
- 1996Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccineInfection and Immunitydoi 10.1128/iai.64.10.4078-4084.199696 citations
Honours
- —Galien Foundation Prix Galien Award
Career
- 1988Joined GlaxoSmithKlineBegan 30-year career in vaccine development at GSK
- 2007Chairman of Global Vaccines at GSKLed development of 14 new vaccines including Cervarix (HPV) and Mosquirix (malaria)
- 2020Chief Scientific Advisor of Operation Warp SpeedLed the US government program that developed COVID-19 vaccines in under a year
Training and certification
- Free University of Brussels
Lineage
We haven't traced this physician's mentors and trainees yet. If you trained with them, you can add to the record.Contribute lineage
FOR THE DOCTOR
Are you Moncef Slaoui?
Claim this record to correct details, add your lineage and teaching, and embed your seal. Claims are checked against your registration before anything changes.